STOCK TITAN
  1. Home
  2. Sec-filings
  3. ABVC
  4. [8-K/A] ABVC BioPharma, Inc. Amends Material Event Report

[8-K/A] ABVC BioPharma, Inc. Amends Material Event Report

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
8-K/A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ABVC logo
Abvc Biopharma Inc

NASDAQ:ABVC

ABVC Rankings

#5126 Ranked by Market Cap
N/A Ranked by Dividends

ABVC Latest News

Dec 19, 2024
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21
Dec 11, 2024
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners
Nov 14, 2024
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones
Oct 22, 2024
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners
Aug 15, 2024
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements

ABVC Latest SEC Filings

Sep 11, 2025
[8-K/A] ABVC BIOPHARMA, INC. Amends Material Event Report
Sep 11, 2025
[8-K/A] ABVC BIOPHARMA, INC. Amends Material Event Report
Sep 11, 2025
[8-K/A] ABVC BIOPHARMA, INC. Amends Material Event Report
Sep 11, 2025
[8-K/A] ABVC BIOPHARMA, INC. Amends Material Event Report
Aug 15, 2025
[424B4] ABVC BioPharma, Inc. Prospectus Filed Pursuant to Rule 424(b)(4)

ABVC Stock Data

71.57M
20.78M
11.73%
1.56%
2.98%
Biotechnology
Pharmaceutical Preparations
Link
United States
FREMONT